philosophy

Innovations@Getwell

Philosophy

Cancer is a disease of hope and optimism. Innovation for us begins with identifying the gaps the caregiver is facing, whether the physician or a family relative, which thus guides us in improvising on our products to provide a better one. We strongly believe that if a slight modification in the product offering can bring a significant positive difference to the patient, then it is worth exploring and achieving without much disruption in the economics of the therapy.
philosophy

Innovation Goals

innovation-goals
Improving patient compliance by developing drug delivery platforms of already existing products that aid in reducing drug’s toxic side effects and/or reduce exposure of cytotoxic drug towards healthy cells. E.g. Liposomes, Nanoparticle and binding with bio-compatible drug carriers.
innovation-goals
Enhancing efficacy by reducing administration errors. This can be achieved by simplifying storage conditions from cold storage to being stable at room temperature and/or by reducing the steps of reconstitution.

Key Products Developed and Commercialized

I-Dox® – Doxorubicin Hcl Liposome Injection (As Pegylated Liposome)

Using an age old well-proven anthracycline drug, Doxorubicin, as an active compound, coating with compatible lipids and reducing its size to less than 100nm, thus leading to a highly efficient targeted delivery in cases of platinum sensitive recurrent ovarian carcinoma, metastatic breast cancer and AIDS- related Kaposi sarcoma.
Representation(s): 20mg/10ml, 50mg/25ml

 

i-dox

Taxe-Rtu-120mg

Taxe-RTU® – Docetaxel Injection

One Vial Formulation.Ready to add to infusion solution. Stable at room temperature.
Representation(s): 20ml/ml, 80mg/4ml, 120mg/6ml

 


Lyophilization of complex compounds, such as


Innovation Pipeline

  • Paclitaxel Injection (Albumin bound) in Nanoparticle form 100mg
    Brand Equivalent: Abraxane
  • Azacitidine for Injection 100mg
    Brand Equivalent: Vidaza
  • Carmustine for Injection 100mg
    Brand Equivalent: BiCNU